Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody
K. Yamanaka, M. Hashimoto, T. Kinoshita, Y. Fujita, S. Matsumura, T. Imanaka, A. Taniguchi, T. Yoshida, H. Kishikawa
Department of Kidney Transplantation Center, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan
*Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…
2020 American Transplant Congress
Health Professional Level Barriers to Living Donor Kidney Transplantation: A Mixed Methods Study
R. Iskander¹, M. Cantarovich¹, N. Dendukuri¹, M. Fortin², S. Sandal¹
¹McGill University, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada
*Purpose: Despite the benefits of living donor kidney transplantation (LDKT), rates have stagnated. Efforts to increase LDKT have focused on patient level barriers. Health professionals…
2020 American Transplant Congress
Incidence and Risk Factors of Post-Transplant Erythrocytosis in Deceased Donor Kidney Transplantation
S. Alasfar, Y. Jia, I. E. Hall, H. Thiessen Philbrook, S. G. Mansour, M. D. Doshi, S. Mohan, J. S. Bromberg, P. P. Reese, C. Parikh
DDS Consortium, Baltimore, MD
*Purpose: Post-transplant erythroytosis (PTE) is clinically important condition after kidney transplantation (KTx). Previously published literature from single-center studies, demonstrated variable incidence rates between 8-15%. We…
2020 American Transplant Congress
Can a Patient with Von Willebrand Disease Donate a Kidney?
Y. Marie¹, W. McKane¹, R. Maclean², R. Pararajasingam¹
¹Renal Transplantation, Sheffield Kidney Institute, Sheffield, United Kingdom, ²Haematology, Sheffield Teaching Hospitals, Sheffield, United Kingdom
*Purpose: Von Willebrand disease (VWD) is a haematological condition that can be challenging to deal with during any operative intervention. We report a successful example…
2020 American Transplant Congress
Late Pneumocystis Jirovecii Pneumonia Often Misdiagnosed
M. Samaniego¹, R. Prashar¹, N. Khoury², A. Patel²
¹Transplant Institute, Henry Ford Health System, Detroit, MI, ²Transplant Institute, Henry Ford Health System, Ann Arbor, MI
*Purpose: Since 2/2018, we have identified 60 transplant recipients presenting with late PCR confirmed Pneumocystis jirovecii (PJP). Of this initial group, 17 kidney transplant recipients…
2020 American Transplant Congress
Optimal Transition for Transplant Recipients: A Model of Care in an Integrated Health Care System
S. Zheng¹, L. Pravoverov¹, A. Nazarova¹, D. Adey², N. B. Goes¹
¹The Permanente Medical Group, San Francisco, CA, ²Kidney and Transplantation Program, University of California San Francisco, San Francisco, CA
*Purpose: Transplantation is the treatment of choice for ESRD. While short-term outcomes have improved, long-term outcomes lag. Many factors may explain the long-term lag including…
2020 American Transplant Congress
Laparoscopic Donor Nephrectomy – Call for a Selective Radical Approach
A. Vijay¹, M. Cooper², J. Verbesey², P. Abrams², S. Yi², S. Ghasemian²
¹Transplant Surgery, University of North Carolina, Chapel Hill, NC, ²Transplant Surgery, Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: Introduction: Retrieval of kidneys in obese donor with excessive peri-renal fat has been reported to be more technically challenging with increased incidence of surgical…
2020 American Transplant Congress
Lateral Flow Assay to Detect Soluble CD25 after Kidney Transplantation
L. K. Seiler, C. Blume, R. Jonczyk
Faculty of Natural Sciences, Institute of Technical Chemistry, Hannover, Germany
*Purpose: Kidney transplantations are one of the most common transplantations in the world; 80.696 kidneys were transplanted in 2017. Despite tremendous improvements in quality and…
2020 American Transplant Congress
Follow Up of Imlifidase (IdeS) Desensitized Kidney Transplant Recipients
S. C. Jordan¹, R. A. Montgomery², T. Lundgren³, C. Legendre⁴, N. Desai⁵, G. Eckerwall⁶, L. Laxmyr⁶, H. Olsson⁶, A. Runström⁶, Å. Schiött⁶, K. Sjöholm⁶, E. Sonesson⁶, L. Winstedt⁶, T. Lorant⁷, C. Kjellman⁶
¹Cedars Sinai Medical Center, Los Angeles, CA, ²NYU Langone Health Transplant Institute, New York, NY, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Hospital Necker & Paris Descartes University, Paris, France, ⁵Johns Hopkins University, Baltimore, MD, ⁶Hansa Biopharma AB, Lund, Sweden, ⁷Uppsala University, Uppsala, Sweden
*Purpose: 46 highly sensitized patients received kidney transplants after desensitization with imlifidase (currently under investigation) across four Phase 2 clinical trials, and 6-month safety and…
2020 American Transplant Congress
The Eplet-Mismatch Landscape in Kidney Patients and Deceased Donors in British Columbia
J. Tran¹, O. Gunther², J. Lan¹, M. Kadatz¹, R. Sapir-Pichhadze³, P. A. Keown¹
¹University of British Columbia, Vancouver, BC, Canada, ²Gunther Analytics, Vancouver, BC, Canada, ³McGill University, Montreal, QC, Canada
*Purpose: Minimizing quantitative donor/recipient mismatch at the HLA epitope level may optimize graft outcomes in renal transplantation, but the degree to which optimal matching can…